Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21369363 | 0.83 | NQO2 (0.37) | ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5573226 | 0.78 | FFAR4 (0.40) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL17132321 | 0.75 | MAPT (0.41) | KDM4EMAPTGAAHPGDL3MBTL1 | |
| SCHEMBL13534196 | 0.75 | HPGD (0.33) | KDM4EGAAALDH1A1TSHRHPGD | |
| SCHEMBL30330238 | 0.75 | MAPT (0.41) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL25166136 | 0.75 | MAPT (0.41) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL13534197 | 0.75 | MAP3K14 (0.42) | KDM4EGAAALDH1A1TSHRHPGD | |
| SCHEMBL13534207 | 0.75 | LMNA (0.42) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL31520283 | 0.75 | MAPT (0.41) | KDM4EMAPTGAAALDH1A1ITGB2 | |
| SCHEMBL12184928 | 0.75 | PLK1 (0.53) | KDM4EMAPTGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| EP-2386558-A1 | CGRP antagonists | Boehringer Ingelheim International GmbH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-5965595-A | SIDE EFFECT REDUCTION; TREATING NASAL CONGESTION AND OTHER ALPHA-2 ADRENORECEPTOR MODULATED DISORDERS, WILL NOT CAUSE HYPERTENSION | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| US-5914342-A | 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| US-5663189-A | RESPIRATORY, EYES, GASTROINTESTINAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | KDM4E 2384/4885MAPT 406/4885GAA 523/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | KDM4E 2170/4885MAPT 517/4885GAA 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.